Exelixis (Exelixis) Scaled Net Operating Assets

: 0.49 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Exelixis's operating assets for the quarter that ended in Dec. 2023 was $1,947 Mil. Exelixis's operating liabilities for the quarter that ended in Dec. 2023 was $489 Mil. Exelixis's Total Assets for the quarter that ended in Sep. 2023 was $2,977 Mil. Therefore, Exelixis's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.49.

Exelixis Scaled Net Operating Assets Historical Data

The historical data trend for Exelixis's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

0.62

0.38

0.37

0.52

0.48

Exelixis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Scaled Net Operating Assets																0.46	0.47	0.46	0.46	0.49

Competitive Comparison

For the Biotechnology subindustry, Exelixis's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exelixis Scaled Net Operating Assets Distribution

For the Biotechnology industry and Healthcare sector, Exelixis's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Exelixis's Scaled Net Operating Assets falls into.

Exelixis Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Exelixis's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(1947.055	-	488.501)	/	3071.489
=	0.47

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2942.357	-	995.302
=	1947.055

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	678.445	-	189.944	-	0
=	488.501

Exelixis's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Sep. 2023 )
=	(1947.055	-	488.501)	/	2976.91
=	0.49

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2942.357	-	995.302
=	1947.055

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	678.445	-	189.944	-	0
=	488.501

Exelixis Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Exelixis's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis (Exelixis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Executives

Patrick J. Haley	officer: Sr. Vice President, Commercial	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel	officer: EVP and General Counsel	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson	director	590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab	officer: CSO/EVP Disc & Trans Research	EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson	officer: EVP Prod Dev & Med Aff & CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner	officer: EVP and CFO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp	director, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski	director	SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber	director	3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum	director	C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb	officer: EVP, Discovery Research & CSO	PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083